Veeco Instruments Inc. today announced that it has introduced its new TurboDisc E475 As/P Metal Organic Chemical Vapor Deposition (MOCVD) system to be used in the production of red, orange, yellow (R/O/Y) high-brightness light emitting diodes (HB-LEDs) and multi-junction III-V concentrator solar cells, primarily for space applications.
Pure H2O, Inc., a provider of novel water and wastewater treatment systems, is pleased to announce that it has been approached by several interested parties with regards to Canadian distribution of its soon to be commercialized under sink unit.
In response to recent technological breakthroughs and a doubling of research and development funding by Octillion Corp, the Company is pleased to announce that, in addition to recently added managerial and support staff, it has increased its research staff to four, with plans to further boost research personnel, contingent upon ongoing results from the development of the Company's first-of-its-kind transparent glass window capable of generating electricity.
Applied Nanoscience, Inc. today announced that it will coordinate all of the necessary remaining tests to have Emergency Filtration Products, Inc., its proposed merger partner, file a new 510(k) notification for the NanoMask with the Food and Drug Administration (FDA).
ThalesNano Inc. announced today that it has launched the latest of its Cube flow reactor series, H-Cube Midi. This novel product is now commercially available and validated with several important chemistry applications.
Chemical Computing Group Inc. (CCG) and Molecular Networks GmbH today announce the integration of CORINA, Molecular Networks' premium three-dimensional molecular model-generating program into CCG's comprehensive and powerful life science modeling suite Molecular Operating Environment (MOE).
BIND Biosciences, Inc., a privately held biopharmaceutical company focused on developing therapeutic targeted nanoparticles, announced today that it has been awarded a six month $150,000 Phase I SBIR contract from the National Cancer Institute to develop a targeted therapy for hormone refractory prostate cancer.